This site is intended for healthcare professionals only

Recognizing exacerbations of COPD and managing underlying inflammation | Japanese

Expert led insights at the physician and patient level

The purpose of this infographic is to broaden the understanding of COPD exacerbations in order to optimize patient care in day-to-day clinical practice by outlining the following:

Nicola A. Hanania


Baylor College of Medicine, Houston

Nicola (Nick) A. Hanania, is Professor of Medicine in the Section of Pulmonary and Critical Care Medicine and director of the Airways Clinical Research Center at the Baylor College of Medicine in Houston, Texas. He also serves on the Faculty Senate at Baylor College of Medicine and is the Chief of Section of Pulmonary, Critical Care and Sleep Medicine at Ben Taub Hospital. Dr Hanania’s research interests focus on the pharmacology and management of asthma and COPD. He has a publication history of more than 320 peer-reviewed papers, book chapters, editorials, and reviews on these topics. His research has been funded by NIH, ALA and industry and focuses on clinical trials investigating novel treatments. He is principal investigator for the American Lung Association Airways Clinical Research Center and COPD Gene study at Baylor College of Medicine, as well as principal investigator or co-investigator in several clinical trials in asthma and COPD. Dr Hanania has received multiple awards, including the ACCP’s Distinguished Scholar in Respiratory Health, Baylor College of Medicine Master Clinician Award, ACCP distinguished CHEST educator (DCE), ACCP Humanitarian Award, Career Investigator Award (K23) from the National Institutes of Health, Fulbright and Jaworski’s Faculty Excellence Award for Teaching and Evaluation, and the Award for Excellence in Teaching from the Department of Medicine at Baylor College of Medicine. He is editor-in-chief of Respiratory Medicine and is associate editor of the journals, Current Opinion in Pulmonary Medicine (Asthma Section), and Lung. He serves on the editorial board of Therapeutic Advances in Respiratory Disease, Pulmonary Pharmacology and Therapeutics, COPD (J of COPD Foundation).

Register your interest

After registering we’ll provide you with:


This educational program is financially supported by Sanofi and Regeneron. The content and faculty for this program have been independently developed and/or selected by Springer Healthcare.